UBS O'Connor’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-445,171
| Closed | -$1.99M | – | 881 |
|
|
2021
Q1 | $1.99M | Buy |
445,171
+295,171
| +197% | +$1.32M | 0.03% | 474 |
|
|
2020
Q4 | $544K | Sell |
150,000
-150,000
| -50% | -$544K | 0.01% | 397 |
|
|
2020
Q3 | $1.16M | Sell |
300,000
-372,035
| -55% | -$1.44M | 0.03% | 196 |
|
|
2020
Q2 | $2.55M | Buy |
+672,035
| New | +$2.55M | 0.06% | 200 |
|
|
2018
Q1 | – | Sell |
-32,448
| Closed | -$215K | – | 328 |
|
|
2017
Q4 | $215K | Hold |
32,448
| – | – | ﹤0.01% | 268 |
|
|
2017
Q3 | $188K | Hold |
32,448
| – | – | ﹤0.01% | 306 |
|
|
2017
Q2 | $272K | Buy |
+32,448
| New | +$272K | ﹤0.01% | 343 |
|
|
2017
Q1 | – | Sell |
-400,000
| Closed | -$1.78M | – | 433 |
|
|
2016
Q4 | $1.78M | Buy |
+400,000
| New | +$1.78M | 0.03% | 314 |
|